Cell MedX Corp.’s eBalance Home System Receives Class II Medical Device License from Health Canada
Carson City, Nevada, July 22, 2020, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is happy to announce that on July 17, 2020, Health Canada granted Cell MedX (Canada) Corp., the Company’s wholly-owned subsidiary, a Class II Medical Device License for its innovative eBalance Home System.
The License #104925 was issued in accordance with the Medical Device Regulations, Section 36.
eBalance Home System
The eBalance Home System is a non-invasive, fully automated microcurrent electrotherapy system that administers pre-programmed algorithms through the epidermis with the touch of a button. The eBalance Home System includes the eBalance Console which acts as the central controller for three (3) pre-programmed microcurrent algorithms (Wellness, Pain Management, & Dual) referred to as Treatment Options. Treatments are administered using Hand Bars and Foot Plates along with the proprietary ePro Gel specially formulated to aid in the conduction of microcurrent. The general wellness and pain management treatment duration and treatment intensity are controlled by the eBalance Console. The eBalance Home System is a safe, effective, easy-to-use therapeutic option for those wanting to use frequency-specific microcurrent for pain relief and general relaxation at home.
Frank McEnulty, the Company’s CEO and Director, stated, “An important key aspect of our mission is to promote healthier lifestyles that offer individuals the opportunity to live their best lives through wellness, and with the Class II Medical License for our eBalance Home System we gained a wider avenue to serve our community.”
About Cell MedX Corp.
Cell MedX Corp. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson’s disease, high blood pressure, neuropathy and kidney function. The final report on the Observational Clinical Trials has been received by Health Canada. For more information about the Company and its technology please visit the Company’s website at www.cellmedx.com/investors/overview/. For the Company’s newsletter please visit www.cellmedx.com/media/newsletters/
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
CEO, Director
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, and Annual Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
The information presented in this press release, including the statements made regarding the eBalance® device, have not been evaluated by the Food and Drug Administration or Health Canada, nor has it been peer reviewed. eBalance® should not be viewed as a substitute for professional medical advice, diagnosis, or treatment. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
SOURCE:
Cell MedX Corp.
For further information visit: www.cellmedx.com.
Investor Relations: 1-310-409-6614